NDC 51525-0115-01 - Hyoscyamine ER
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 51525-0115
- Requested NDC
- 51525-0115-01
- Package NDCs from labels
- 51525-0115-1, 51525-0115-01
- Manufacturer
- Mylan Pharmaceuticals Inc.
- Effective date
- 2023-07-15
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Hyoscyamine Sulfate Extended-Release Tablets, 0.375 mg Rx only | Mylan Pharmaceuticals Inc. | 2023-07-15 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 51525-0115-1 | HyoscyamineER | 100 in 1 BOTTLE | TABLET, EXTENDED RELEASE | 100 | 4 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 51525-0115 | HYOSCYAMINE ER (HYOSCYAMINE SULFATE) TABLET, EXTENDED RELEASE [WALLACE PHARMACEUTICALS INC.] | 3 | Current NDC, Legacy NDC, 1 package rows | 20181219_5bbce8c0-a9c9-45b9-8457-1542bd3d9449.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 51525-0115-1 | EA - Each | 51525-0115 | 85cd83a7-0a00-424b-8c00-f285e52ec8aa | 1 | 2016-07-19 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Hyoscyamine Sulfate | HYOSCYAMINE SULFATE | Bryant Ranch Prepack | 57b26b7f-f22d-4ffb-a748-d430572f92a7 | 2023-04-12 | Warnings, Adverse reactions | F2R8V82B84 |
| Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide | PHENOBARBITAL, HYOSCYAMINE SULFATE, ATROPINE SULFATE, SCOPOLAMINE HYDROBROMIDE | Ingenus Pharmaceuticals, LLC | 33bf2df5-bc53-4d57-a9e7-41f3fc0a03f0 | 2023-01-12 | Warnings, Adverse reactions | F2R8V82B84 |
| Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate and Scopolamine Hydrobromide | PHENOBARBITAL, HYOSCYAMINE SULFATE, ATROPINE SULFATE AND SCOPOLAMINE HYDROBROMIDE | Ingenus Pharmaceuticals, LLC | 0dd71f55-e009-48dd-809d-5f651f7521de | 2023-01-10 | Warnings, Adverse reactions | F2R8V82B84 |
| Donnatal | PHENOBARBITAL, HYOSCYAMINE SULFATE, ATROPINE SULFATE, SCOPOLAMINE HYDROBROMIDE | VistaPharm, LLC | 11a48ba9-576b-4e8c-9536-6e83636d6930 | 2022-07-07 | Warnings, Adverse reactions | F2R8V82B84 |
| Phenohytro | PHENOBARBITAL, HYOSCYAMINE SULFATE, ATROPINE SULFATE, SCOPOLAMINE HYDROBROMIDE | Winder Laboratories, LLC | 27c8baac-f8ce-46d8-8a0f-ff769dd408d9 | 2019-12-27 | Warnings, Adverse reactions | F2R8V82B84 |
| Phenohytro | PHENOBARBITAL, HYOSCYAMINE SULFATE, ATROPINE SULFATE, AND SCOPOLAMINE HYDROBROMIDE | Winder Laboratories LLC | 29be31ef-108e-4b45-9ecc-b6d671da2826 | 2019-10-04 | Warnings, Adverse reactions | F2R8V82B84 |
| URELLE | HYOSCYAMINE SULFATE, METHENAMINE, METHYLENE BLUE, PHENYL SALICYLATE, AND SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | Viatris Specialty LLC | 1d80a11c-6f86-403b-85d4-32ec1924dbe9 | 2015-01-13 | Warnings, Adverse reactions | F2R8V82B84 |
| Levsin SL | HYOSCYAMINE SULFATE | Viatris Specialty LLC | f38ece41-b890-11e2-9e96-0800200c9a66 | 2013-05-14 | Warnings, Adverse reactions | F2R8V82B84 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.